Optimising treatment dosing for inflammatory disorders such as RA is as complex as the disorders themselves, new research from Norway has shown. In one RA study trialling a 50% dose reduction of csDMARDs versus standard dosing in RA patients in remission, researchers found a significant increase in flares over 12 months in the half-dose group. ...
TDM and dose reductions won’t benefit all patients but worth it for some
By Mardi Chapman
18 May 2021